Clinical trials: Mask Induction
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Allergic Conjunctivitis
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
The purpose of this study is to evaluate the safety, efficacy, and dose response of brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of allergen-induced conjunctival redness using a conjunctival…
- Trial name
- NCT01275105
- Testing
- Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Eye Therapies, LLC
Non-Proliferative Diabetic Retinopathy
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.
- Trial name
- NCT02435862
- Testing
- 1.0mg Luminate®, 2.0mg Luminate®, 3.0mg Luminate®
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Allegro Ophthalmics, LLC
Myopia
Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children
This study is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of atropine sulfate eye drops (0.01%) in treating transient myopia induced by near work tasks (NITM) in…
- Trial name
- NCT06697522
- Testing
- Atropine Sulfate
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Ocumension Therapeutics (Suzhou) Co., Ltd
Vitreomacular Traction
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with vitreomacular traction.
- Trial name
- NCT00435539
- Testing
- ocriplasmin
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 60 people
- Sponsor
- ThromboGenics
Viral Conjunctivitis
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC.
- Trial name
- NCT01977443
- Testing
- APD-209 Eye drops
- Where
- 10 sites in Germany, Poland and 1 more
- Volunteers
- 47 people
- Sponsor
- Adenovir Pharma AB
Vitrectomy
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
- Trial name
- NCT00412958
- Testing
- Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg
- Where
- 20 sites in United States
- Volunteers
- 125 people
- Sponsor
- ThromboGenics
Eyelash Hypotrichosis
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes following chemotherapy treatment.
- Trial name
- NCT01391286
- Testing
- bimatoprost solution 0.03%, bimatoprost vehicle solution
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Allergan
Mydriasis, Dilation
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
The objectives of this study are: To evaluate the safety of Nyxol in pediatric subjects To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically induced mydriasis in pediatric subjects The Sponsor intends…
- Trial name
- MIRA-4 (NCT05223478)
- Testing
- Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
- Trial name
- NCT00241319
- Testing
- R89674 (generic name not yet established)
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Vistakon Pharmaceuticals
Allergic Conjunctivitis
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat".
- Trial name
- NCT07675811
- Testing
- REGN-2Cat, Freneslerbart, Mevonlerbart
- Where
- United States
- Volunteers
- 570 people
- Sponsor
- Regeneron Pharmaceuticals
Uveitis
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
- Trial name
- INSURE (NCT01103024)
- Testing
- AIN457
- Where
- 11 sites in United States, Canada and 3 more
- Sponsor
- Novartis
Mydriasis, Dilation
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
The objectives of this study are: To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis To evaluate the safety of Nyxol To evaluate the effect of…
- Trial name
- NCT04024891
- Testing
- Phentolamine Mesylate Ophthalmic Solution 1%
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Uveitis
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- INSURE (NCT01095250)
- Testing
- AIN457
- Where
- 36 sites in United States, Canada and 11 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Mydriasis, Dilation
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
The objectives of this study are: To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine To evaluate the efficacy of…
- Trial name
- MIRA-3 (NCT05134974)
- Testing
- Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
- Where
- 15 sites in United States
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
- Trial name
- NCT00244543
- Testing
- R89674 (generic name not yet established)
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Radiodermatitis, Dermatitis, Radiation-Induced
Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.
This is a post marketing, interventional, randomized, single-center, prospective, controlled study, for the evaluation of the clinical performance and tolerability of a cream-based medical device (DermoRelizemaTM cream) in the…
- Trial name
- DRESDA (NCT04483856)
- Testing
- DermoRelizema cream, Dexeryl
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Relife Italia S.r.l.
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Atopic Asthma
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects with Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
- Trial name
- NCT04728711
- Testing
- ADX-629
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Mydriasis, Dilation
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
The objectives of this study are: To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine To evaluate the efficacy of…
- Trial name
- NCT04620213
- Testing
- Phentolamine Ophthalmic Solution 0.75%
- Where
- 12 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc